造血干细胞移植中白消安血药浓度监测及其临床意义Plasma Busulfan Concentration Monitoring and Clinical Benefit in Hematopoietic Stem Cell Transplantation
张耀东
ZHANG Yao-dong (Pharmacy Department of Shenzhen Hosptial
摘要(Abstract)：
目的综述白消安在造血干细胞移植预处理方案中的应用及其血药浓度监测研究进展。方法查阅国内外相关文献,对有代表性的文献进行分析、归纳、总结。结果白消安的血药浓度与治疗结果相关,适宜的治疗窗能提高疗效,减少药物不良反应和降低移植后并发症的风险。结论对白消安进行血药浓度监测和剂量调整有重要的临床意义。
Objective To review the application of busulfan in conditioning therapy in hematopoietic stem cell transplantation(HSCT) and the progress of monitoring busulfan plasma levels.Methods The correlate literature was searched,and topical ones were selected to analyze.Results The concentration of busulfan in plasma was related with the treatment outcome,and the appropriate therapeutic window could enhance the clinical effect and diminish the risk of adverse drug reaction and complication after the transplantation.Conclusion Monitoring busulfan plasma levels and adjusting its dosage can benefit patients greatly.
关键词(KeyWords)：
白消安;血药浓度;疗效;不良反应
busulfan;plasma drug concentration;efficacy;adverse drug reaction
基金项目(Foundation):
作者(Author):
张耀东
ZHANG Yao-dong (Pharmacy Department of Shenzhen Hosptial
参考文献(References)：
- 1 Anderson BS,Kashyap A,Gian V,et aI.Conditioning therapywith intravenous busulfan and cyclophosphamide(IV BuCy2)for hematologic malignancies prior to allogeneic stem celltransplantation:Aphase II study.Biol Blood MarrowTransplantation,2002,8(3):145-154.
- 2 Hassan M,Ljungman P,Bolme P,et aI.Busulfan bioavail-ability.Blood,1994,84:2144-2150.
- 3 Kashyap A,Wingard J,Cagnoni P,et aI.Intravenous versusoral busulfan as part of a busulfan/cyclophosphamide preparativeregimen for allogeneic hematopoietic stem cell transplantation:decreased incidence of hepatic venocclusive disease(HVOD),HVOD-related mortality,and overall 100-day mortality.BiolBlood MarrowTransplantation,2002,8(9):493-500.
- 4 Hassan M,Nilsson C,Hassan Z,et aI.Bone MarrowTransplantation,2002,30:833.
- 5 Vassal G,Koscielnv S,Challine D,et aI.Busulfandispositionand hepatic veno-occlusive disease in childrenundergoingbone marrow transplantation.Cancer ChemotherPharmacol,1996,37(3):247-253.
- 6 Grochow LB.Busulfan disposition:the role of therapeuticmonitoring in bone marrow transplantation induction regimens.Semin Oncol,1993,20(4):18-25.
- 7 GrochowLB,Jones RJ,Brundrett RB,et aI.Pharmacokineticsof busulfan:correlation with veno-occlusive disease inpatients undergoing bone marrow transplantation.Cancer ChemotherPharmacol,1989,25(1):55-61.
- 8 Slattery JT.Intravenous versus oral busulfan——perhaps notas different as suggested.Biol Blood Marrow Transplant,2002,8(9):493-500.
- 9 Andersson BS,Thall PF,Madden T,et aI.Busulfan systemicexposure relative to regimen-related toxicity and acute graft-versus-host disease:defining a therapeutic window for i.v.BuCy2 in chronic myelogenous leukemia.Biol Blood MarrowTransplant,2002,8(9):465-467.
- 10 Hoffer E,Akria L,Acherb I,et aI.A simple approximationfor busulfan does adjustment in adult patient undergoing bonemarrow transplantation.Ther Drug Monit,2004,26(3):331-335.
- 11 Andersson BS,Kashyap A,Gian V,et aI.Conditioningtherapy with intravenous busulfan and cyclophosphamide(IVBuCy2)for hematologic malignancies prior to allogeneic stemcell transplantation:a phase II study.Biol Blood MarrowTransplant,2002,8(3):145-154.
- 12 Andersson BS,Madden T,Tran HT,et aI.Acute safety andpharmacokinetics of intravenous busulfan when used with oralbusulfan and cyclophosphamide as pretransplantationconditioning therapy:a phase I study.Biol Blood MarrowTransplant,2000,6(5):548-554.